Market Spotlight: Pancreatic Cancer
Market Spotlight: Pancreatic Cancer
$1,318.00
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were 453,200 incident cases of pancreatic cancer worldwide, and expects that number to increase to 495,900 incident cases by 2026.
- The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor. These are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.
- The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II. Therapies in development for pancreatic cancer focus on a wide variety of targets. The majority of pipeline drugs for pancreatic cancer are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase II and Phase III trial results, and patent expirations.
- The overall likelihood of approval of a Phase I pancreatic cancer asset is 2.3%, and the average probability a drug advances from Phase III is 13.6%. Drugs, on average, take 10.3 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
- There have been 44 licensing and asset acquisition deals involving pancreatic cancer drugs during 2014–19. The $1,770m exclusive clinical collaboration agreement signed in 2014 between Bristol-Myers Squibb and Five Prime Therapeutics to explore the combination of Opdivo with FPA008 in six tumor types, including pancreatic cancer, was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for pancreatic cancer have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
- The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the pancreatic cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 93 trials.
- Roche leads the industry sponsors with the highest number of clinical trials for pancreatic cancer, followed by Eli Lilly
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Pancreatic cancer subtypes
10 TREATMENT
10 Surgery
10 Ablation or embolization
11 Radiation therapy
11 Chemotherapy
11 Targeted therapy
12 Immunotherapy
12 Drugs used specifically for treatment of PNETs
13 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
39 RECENT EVENTS AND ANALYST OPINION
39 SM-88 for pancreatic cancer (January 18, 2019)
40 BL-8040 for pancreatic cancer (October 19, 2018)
42 AM0010 for pancreatic cancer (June 3, 2018)
44 ERY-ASP for pancreatic cancer (September 8, 2017)
47 KEY UPCOMING EVENTS
48 KEY REGULATORY EVENTS
48 Lutathera’s Broad Tumor Indication Aided By Expanded Access Data
49 PROBABILITY OF SUCCESS
50 LICENSING AND ASSET ACQUISITION DEALS
50 Servier Acquires Shire Oncology Business For $2.4bn
51 PARENT PATENTS
53 REVENUE OPPORTUNITY
55 CLINICAL TRIAL LANDSCAPE
56 Sponsors by status
57 Sponsors by phase
58 Recent events
59 BIBLIOGRAPHY
59 Prescription information
61 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of pancreatic cancer, 2017–26
19 Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
19 Figure 3: Pipeline drugs for pancreatic cancer, by company
20 Figure 4: Pipeline drugs for pancreatic cancer, by drug type
20 Figure 5: Pipeline drugs for pancreatic cancer, by classification
40 Figure 6: SM-88 for Pancreatic Cancer (January 18, 2019): Phase II – Tyme-88-Panc (>1L)
42 Figure 7: BL-8040 for Pancreatic Cancer (October 19, 2018): Phase IIa – COMBAT/KEYNOTE-202 (w/Keytruda)
44 Figure 8: AM0010 for Pancreatic Cancer (June 3, 2018): Phase I/Ib – 001
46 Figure 9: ERY-ASP for Pancreatic Cancer (September 8, 2017): Phase IIb – +/-SOC (EU)
47 Figure 10: Key upcoming events in pancreatic cancer
49 Figure 11: Probability of success in the pancreatic cancer pipeline
50 Figure 12: Licensing and asset acquisition deals in pancreatic cancer, 2014–19
51 Figure 13: Parent patents in pancreatic cancer, 2019–24
52 Figure 14: Parent patents in pancreatic cancer, 2024–29
52 Figure 15: Parent patents in pancreatic cancer, 2029–38
55 Figure 16: Clinical trials in pancreatic cancer
55 Figure 17: Top 10 drugs for clinical trials in pancreatic cancer
56 Figure 18: Top 10 companies for clinical trials in pancreatic cancer
56 Figure 19: Trial locations in pancreatic cancer
57 Figure 20: Pancreatic cancer trials status
58 Figure 21: Pancreatic cancer trials sponsors, by phase
LIST OF TABLES
14 Table 1: Incident cases of pancreatic cancer, 2017–26
17 Table 2: Marketed drugs for pancreatic cancer
21 Table 3: Pipeline drugs for pancreatic cancer in the US
39 Table 4: SM-88 for Pancreatic Cancer (January 18, 2019)
41 Table 5: BL-8040 for Pancreatic Cancer (October 19, 2018)
42 Table 6: AM0010 for Pancreatic Cancer (June 3, 2018)
45 Table 7: ERY-ASP for Pancreatic Cancer (September 8, 2017)
53 Table 8: Historical global sales, by drug ($m), 2013–17
54 Table 9: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the